Okomera is a pioneering figure in the automation and miniaturization of personalized tumor biopsy studies.
Okomera’s 3D technology is currently used for testing patient samples, and will be included later on in clinical trials.
Our aim is to become the gold standard in functional precision medicine, having our devices installed at cancer centers around the world. We want to improve patient outcomes by screening the tumor biopsy for different treatments, and finding the most efficient one for each and every patient.
Sidarth Radjou - CEO